Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine preventionTony W. Ho, David Michelson, Kathryn M. Connor et al.|Neurology|2014Cited by 263
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraineDavid Hewitt, Tony W. Ho, Sheena K. Aurora et al.|Cephalalgia|2011Cited by 263
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung Min Lee, Elise C. Kohn, Ashley Cimino‐Mathews et al.|Journal of Clinical Oncology|2017Cited by 241
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren Hodgson, J. Carl Barrett, Brian Dougherty et al.|British Journal of Cancer|2018Cited by 233
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyUrsula A. Matulonis, Robert L. Coleman, Richard T. Penson et al.|Annals of Oncology|2016Cited by 159